Live symbol workspace

MRNA market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Status Chart ready

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for MRNA skewed bullish (3 of 6 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

34%

▲ 0.8 pts vs previous week

Avg confidence across 18 calls in the last 7 days

What sources say

Bullish 3 articles

Merck, Moderna Stocks Soar After Melanoma Trial Success

Merck, Moderna Melanoma Vaccine Study Succeeds

RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers

Neutral 3 articles

Moderna’s stock doubles on promising cancer-vaccine results

Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Slips.

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

MRNA News Intelligence (12 articles)

AI-curated news influencing MRNA price, sentiment, and trend

Explore All MRNA News with AI Analysis

Economy

42 minutes ago

Merck, Moderna Stocks Soar After Melanoma Trial Success

Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising …

Impact on MRNA: Potentially positive price action expected

Analysis of stock market developments showing bullish sentiment. Medium (60%)

View full analysis →

Bloomberg 60% confidence

Economy

1 hour, 27 minutes ago

Merck, Moderna Melanoma Vaccine Study Succeeds

Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced …

Impact on MRNA: Potentially positive price action expected

Financial market analysis indicating bullish sentiment based on current trends. Medium (60%)

View full analysis →

Bloomberg 60% confidence

Stocks

2 hours, 54 minutes ago

Moderna’s stock doubles on promising cancer-vaccine results

The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.

Impact on MRNA: Neutral market sentiment indicated

Analysis of stock market developments showing neutral sentiment. Medium (50%)

View full analysis →

MarketWatch 50% confidence

Economy

1 week, 1 day ago

RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers

On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from …

Impact on MRNA: Potentially positive price action expected

Analysis of stock market developments showing bullish sentiment. Medium (60%)

View full analysis →

Bloomberg 60% confidence

Economy

1 week, 6 days ago

Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Slips.

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

Impact on MRNA: Neutral market sentiment indicated

Analysis of stock market developments showing neutral sentiment. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

2 weeks ago

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.

Impact on MRNA: Neutral market sentiment indicated

Analysis of stock market developments showing neutral sentiment. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence